StageZero Life Sciences's quarterly market cap
declined
from Sep. 2023 ($4.96 Mil) to Mar. 2024 ($4.33 Mil) and
declined
from Mar. 2024 ($4.33 Mil) to Jun. 2024 ($0.19 Mil).
StageZero Life Sciences's annual market cap
declined
from Dec. 2020 ($35.51 Mil) to Dec. 2021 ($20.90 Mil) and
declined
from Dec. 2021 ($20.90 Mil) to Dec. 2022 ($4.67 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. StageZero Life Sciences's Enterprise Value for Today is $2.26 Mil.
StageZero Life Sciences Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of StageZero Life Sciences's Market Cap
For the Diagnostics & Research subindustry, StageZero Life Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StageZero Life Sciences's Market Cap Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where StageZero Life Sciences's Market Cap falls into.
StageZero Life Sciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
StageZero Life Sciences's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StageZero Life Sciences (OTCPK:SZLSF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
StageZero Life Sciences Market Cap Related Terms
Thank you for viewing the detailed overview of StageZero Life Sciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZLSF has been successfully added to your 